What Is the Mechanism Driving the Reduction of Cardiovascular Events from Glucagon-like Peptide-1 Receptor Agonists?—A Mini Review

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are considered the standard of care for type 2 diabetes in many countries worldwide. These molecules have profound anti-hyperglycaemic actions with a favourable safety profile. They are now being considered for their robust cardiovascular (CV) pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Berndt, Jared, Ooi, Soo Liang, Pak, Sok Cheon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8400553/
https://www.ncbi.nlm.nih.gov/pubmed/34443410
http://dx.doi.org/10.3390/molecules26164822

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8400553/
https://www.ncbi.nlm.nih.gov/pubmed/34443410
http://dx.doi.org/10.3390/molecules26164822

Ejemplares similares